A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study

Management of cancer-associated venous thromboembolism (VTE) is essential in treatment selection and cancer prognosis. However, to date, there is no method to assess the risk of VTE specifically associated with advanced lung cancer. Our aim was to create a new risk assessment scoring system that can...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2022-04, Vol.15 (1), p.40-40, Article 40
Main Authors: Tsubata, Yukari, Hotta, Takamasa, Hamai, Kosuke, Furuya, Naoki, Yokoyama, Toshihide, Saito, Ryota, Nakamura, Atsushi, Masuda, Takeshi, Hamaguchi, Megumi, Kuyama, Shoichi, Honda, Ryoichi, Senoo, Tadashi, Nakanishi, Masamoto, Yamasaki, Masahiro, Ishikawa, Nobuhisa, Fujitaka, Kazunori, Kubota, Tetsuya, Kobayashi, Kunihiko, Isobe, Takeshi
Format: Article
Language:English
Subjects:
Adenocarcinoma
Asymptomatic
Blood pressure
Cancer
Cancer therapies
Care and treatment
Cell number
Chemotherapy
Deep vein thrombosis
Female
Health aspects
Humans
Letter to the Editor
Lung cancer
Lung Neoplasms - complications
Lymphocytes
Multivariate analysis
Oncology, Experimental
Patients
Prognosis
Prospective Studies
Prothrombin
Prothrombin fragment 1 + 2
Pulmonary thromboembolism
Risk Assessment
Risk Factors
Risk-assessment model
Thrombin
Thromboembolism
Thrombosis
Venous Thromboembolism - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c660t-292e7af0ccabbe1b52cb952ac92ce331412138046a6fb00713b9902f09d298ee3
cites cdi_FETCH-LOGICAL-c660t-292e7af0ccabbe1b52cb952ac92ce331412138046a6fb00713b9902f09d298ee3
container_end_page 40
container_issue 1
container_start_page 40
container_title Journal of hematology and oncology
container_volume 15
creator Tsubata, Yukari
Hotta, Takamasa
Hamai, Kosuke
Furuya, Naoki
Yokoyama, Toshihide
Saito, Ryota
Nakamura, Atsushi
Masuda, Takeshi
Hamaguchi, Megumi
Kuyama, Shoichi
Honda, Ryoichi
Senoo, Tadashi
Nakanishi, Masamoto
Yamasaki, Masahiro
Ishikawa, Nobuhisa
Fujitaka, Kazunori
Kubota, Tetsuya
Kobayashi, Kunihiko
Isobe, Takeshi
description Management of cancer-associated venous thromboembolism (VTE) is essential in treatment selection and cancer prognosis. However, to date, there is no method to assess the risk of VTE specifically associated with advanced lung cancer. Our aim was to create a new risk assessment scoring system that can predict the concomitant or incidence of VTE in advanced lung cancer. We used the dataset of 1008 patients with lung cancer in the Rising-VTE/NEJ037 study, of which 100 (9.9%) developed VTE. The items extracted in the multivariate analysis included female sex, adenocarcinoma, performance status, N factor, lymphocyte count, platelet count, prothrombin fragment 1 + 2, and diastolic blood pressure. This model had a maximum score of 8 points, with ≥ 5 points indicating a high risk of VTE. This simple risk-assessment model for VTE complications with advanced lung cancer could help identify cases that required monitoring for VTE.
doi_str_mv 10.1186/s13045-022-01259-7
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2fea11230a9f4a7eade6668f5a8337d5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A699416750</galeid><doaj_id>oai_doaj_org_article_2fea11230a9f4a7eade6668f5a8337d5</doaj_id><sourcerecordid>A699416750</sourcerecordid><originalsourceid>FETCH-LOGICAL-c660t-292e7af0ccabbe1b52cb952ac92ce331412138046a6fb00713b9902f09d298ee3</originalsourceid><addsrcrecordid>eNptUk1v1DAQjRCIlsIf4IAsISEOpPgjcWIOSKuKj0qVuMDZmjjjXZfE3trJov57nG4puwhZlkfjN280b15RvGT0nLFWvk9M0KouKeclZbxWZfOoOGVNLcu24fzxQXxSPEvpmlLJFKdPixNRi0YJqk6LmxXx-ItEl36WkBKmNKKfyBTCQGyIZIc-zIlMmxjGLmC-g0sjcZ5AvwNvsCfD7NfELHH8QIBsY0hbNJPb4TsSuoRxB5MLHgaSprm_fV48sTAkfHH_nhU_Pn_6fvG1vPr25fJidVUaKelUcsWxAUuNga5D1tXcdKrmYBQ3KASrGGeipZUEaTtKGyY6pSi3VPVctYjirLjc8_YBrvU2uhHirQ7g9F0ixLWGODkzoOYWgTEuKChbQYPQo5SytTW0QjR9nbk-7rm2czdib7JEEYYj0uMf7zZ6HXa6VS1raZMJ3t4TxHAzY5r06JLBYQCPWV_NZdVwxiux9Hr9D_Q6zDHLt6BqppSqJf-LWkMewHkbcl-zkOqVVKpisqlpRp3_B5VPj6MzwaN1OX9U8OagYIMwTJsUhnlZYDoG8j3Q5HWniPZBDEb14k69d6fO7tR37tSLCq8OZXwo-WNH8RvCgd-v</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2651999562</pqid></control><display><type>article</type><title>A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Tsubata, Yukari ; Hotta, Takamasa ; Hamai, Kosuke ; Furuya, Naoki ; Yokoyama, Toshihide ; Saito, Ryota ; Nakamura, Atsushi ; Masuda, Takeshi ; Hamaguchi, Megumi ; Kuyama, Shoichi ; Honda, Ryoichi ; Senoo, Tadashi ; Nakanishi, Masamoto ; Yamasaki, Masahiro ; Ishikawa, Nobuhisa ; Fujitaka, Kazunori ; Kubota, Tetsuya ; Kobayashi, Kunihiko ; Isobe, Takeshi</creator><creatorcontrib>Tsubata, Yukari ; Hotta, Takamasa ; Hamai, Kosuke ; Furuya, Naoki ; Yokoyama, Toshihide ; Saito, Ryota ; Nakamura, Atsushi ; Masuda, Takeshi ; Hamaguchi, Megumi ; Kuyama, Shoichi ; Honda, Ryoichi ; Senoo, Tadashi ; Nakanishi, Masamoto ; Yamasaki, Masahiro ; Ishikawa, Nobuhisa ; Fujitaka, Kazunori ; Kubota, Tetsuya ; Kobayashi, Kunihiko ; Isobe, Takeshi</creatorcontrib><description>Management of cancer-associated venous thromboembolism (VTE) is essential in treatment selection and cancer prognosis. However, to date, there is no method to assess the risk of VTE specifically associated with advanced lung cancer. Our aim was to create a new risk assessment scoring system that can predict the concomitant or incidence of VTE in advanced lung cancer. We used the dataset of 1008 patients with lung cancer in the Rising-VTE/NEJ037 study, of which 100 (9.9%) developed VTE. The items extracted in the multivariate analysis included female sex, adenocarcinoma, performance status, N factor, lymphocyte count, platelet count, prothrombin fragment 1 + 2, and diastolic blood pressure. This model had a maximum score of 8 points, with ≥ 5 points indicating a high risk of VTE. This simple risk-assessment model for VTE complications with advanced lung cancer could help identify cases that required monitoring for VTE.</description><identifier>ISSN: 1756-8722</identifier><identifier>EISSN: 1756-8722</identifier><identifier>DOI: 10.1186/s13045-022-01259-7</identifier><identifier>PMID: 35379309</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adenocarcinoma ; Asymptomatic ; Blood pressure ; Cancer ; Cancer therapies ; Care and treatment ; Cell number ; Chemotherapy ; Deep vein thrombosis ; Female ; Health aspects ; Humans ; Letter to the Editor ; Lung cancer ; Lung Neoplasms - complications ; Lymphocytes ; Multivariate analysis ; Oncology, Experimental ; Patients ; Prognosis ; Prospective Studies ; Prothrombin ; Prothrombin fragment 1 + 2 ; Pulmonary thromboembolism ; Risk Assessment ; Risk Factors ; Risk-assessment model ; Thrombin ; Thromboembolism ; Thrombosis ; Venous Thromboembolism - etiology</subject><ispartof>Journal of hematology and oncology, 2022-04, Vol.15 (1), p.40-40, Article 40</ispartof><rights>2022. The Author(s).</rights><rights>COPYRIGHT 2022 BioMed Central Ltd.</rights><rights>2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c660t-292e7af0ccabbe1b52cb952ac92ce331412138046a6fb00713b9902f09d298ee3</citedby><cites>FETCH-LOGICAL-c660t-292e7af0ccabbe1b52cb952ac92ce331412138046a6fb00713b9902f09d298ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981807/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2651999562?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35379309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsubata, Yukari</creatorcontrib><creatorcontrib>Hotta, Takamasa</creatorcontrib><creatorcontrib>Hamai, Kosuke</creatorcontrib><creatorcontrib>Furuya, Naoki</creatorcontrib><creatorcontrib>Yokoyama, Toshihide</creatorcontrib><creatorcontrib>Saito, Ryota</creatorcontrib><creatorcontrib>Nakamura, Atsushi</creatorcontrib><creatorcontrib>Masuda, Takeshi</creatorcontrib><creatorcontrib>Hamaguchi, Megumi</creatorcontrib><creatorcontrib>Kuyama, Shoichi</creatorcontrib><creatorcontrib>Honda, Ryoichi</creatorcontrib><creatorcontrib>Senoo, Tadashi</creatorcontrib><creatorcontrib>Nakanishi, Masamoto</creatorcontrib><creatorcontrib>Yamasaki, Masahiro</creatorcontrib><creatorcontrib>Ishikawa, Nobuhisa</creatorcontrib><creatorcontrib>Fujitaka, Kazunori</creatorcontrib><creatorcontrib>Kubota, Tetsuya</creatorcontrib><creatorcontrib>Kobayashi, Kunihiko</creatorcontrib><creatorcontrib>Isobe, Takeshi</creatorcontrib><title>A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study</title><title>Journal of hematology and oncology</title><addtitle>J Hematol Oncol</addtitle><description>Management of cancer-associated venous thromboembolism (VTE) is essential in treatment selection and cancer prognosis. However, to date, there is no method to assess the risk of VTE specifically associated with advanced lung cancer. Our aim was to create a new risk assessment scoring system that can predict the concomitant or incidence of VTE in advanced lung cancer. We used the dataset of 1008 patients with lung cancer in the Rising-VTE/NEJ037 study, of which 100 (9.9%) developed VTE. The items extracted in the multivariate analysis included female sex, adenocarcinoma, performance status, N factor, lymphocyte count, platelet count, prothrombin fragment 1 + 2, and diastolic blood pressure. This model had a maximum score of 8 points, with ≥ 5 points indicating a high risk of VTE. This simple risk-assessment model for VTE complications with advanced lung cancer could help identify cases that required monitoring for VTE.</description><subject>Adenocarcinoma</subject><subject>Asymptomatic</subject><subject>Blood pressure</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cell number</subject><subject>Chemotherapy</subject><subject>Deep vein thrombosis</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Letter to the Editor</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - complications</subject><subject>Lymphocytes</subject><subject>Multivariate analysis</subject><subject>Oncology, Experimental</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Prothrombin</subject><subject>Prothrombin fragment 1 + 2</subject><subject>Pulmonary thromboembolism</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Risk-assessment model</subject><subject>Thrombin</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><subject>Venous Thromboembolism - etiology</subject><issn>1756-8722</issn><issn>1756-8722</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1v1DAQjRCIlsIf4IAsISEOpPgjcWIOSKuKj0qVuMDZmjjjXZfE3trJov57nG4puwhZlkfjN280b15RvGT0nLFWvk9M0KouKeclZbxWZfOoOGVNLcu24fzxQXxSPEvpmlLJFKdPixNRi0YJqk6LmxXx-ItEl36WkBKmNKKfyBTCQGyIZIc-zIlMmxjGLmC-g0sjcZ5AvwNvsCfD7NfELHH8QIBsY0hbNJPb4TsSuoRxB5MLHgaSprm_fV48sTAkfHH_nhU_Pn_6fvG1vPr25fJidVUaKelUcsWxAUuNga5D1tXcdKrmYBQ3KASrGGeipZUEaTtKGyY6pSi3VPVctYjirLjc8_YBrvU2uhHirQ7g9F0ixLWGODkzoOYWgTEuKChbQYPQo5SytTW0QjR9nbk-7rm2czdib7JEEYYj0uMf7zZ6HXa6VS1raZMJ3t4TxHAzY5r06JLBYQCPWV_NZdVwxiux9Hr9D_Q6zDHLt6BqppSqJf-LWkMewHkbcl-zkOqVVKpisqlpRp3_B5VPj6MzwaN1OX9U8OagYIMwTJsUhnlZYDoG8j3Q5HWniPZBDEb14k69d6fO7tR37tSLCq8OZXwo-WNH8RvCgd-v</recordid><startdate>20220404</startdate><enddate>20220404</enddate><creator>Tsubata, Yukari</creator><creator>Hotta, Takamasa</creator><creator>Hamai, Kosuke</creator><creator>Furuya, Naoki</creator><creator>Yokoyama, Toshihide</creator><creator>Saito, Ryota</creator><creator>Nakamura, Atsushi</creator><creator>Masuda, Takeshi</creator><creator>Hamaguchi, Megumi</creator><creator>Kuyama, Shoichi</creator><creator>Honda, Ryoichi</creator><creator>Senoo, Tadashi</creator><creator>Nakanishi, Masamoto</creator><creator>Yamasaki, Masahiro</creator><creator>Ishikawa, Nobuhisa</creator><creator>Fujitaka, Kazunori</creator><creator>Kubota, Tetsuya</creator><creator>Kobayashi, Kunihiko</creator><creator>Isobe, Takeshi</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20220404</creationdate><title>A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study</title><author>Tsubata, Yukari ; Hotta, Takamasa ; Hamai, Kosuke ; Furuya, Naoki ; Yokoyama, Toshihide ; Saito, Ryota ; Nakamura, Atsushi ; Masuda, Takeshi ; Hamaguchi, Megumi ; Kuyama, Shoichi ; Honda, Ryoichi ; Senoo, Tadashi ; Nakanishi, Masamoto ; Yamasaki, Masahiro ; Ishikawa, Nobuhisa ; Fujitaka, Kazunori ; Kubota, Tetsuya ; Kobayashi, Kunihiko ; Isobe, Takeshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c660t-292e7af0ccabbe1b52cb952ac92ce331412138046a6fb00713b9902f09d298ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adenocarcinoma</topic><topic>Asymptomatic</topic><topic>Blood pressure</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cell number</topic><topic>Chemotherapy</topic><topic>Deep vein thrombosis</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Letter to the Editor</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - complications</topic><topic>Lymphocytes</topic><topic>Multivariate analysis</topic><topic>Oncology, Experimental</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Prothrombin</topic><topic>Prothrombin fragment 1 + 2</topic><topic>Pulmonary thromboembolism</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Risk-assessment model</topic><topic>Thrombin</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><topic>Venous Thromboembolism - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsubata, Yukari</creatorcontrib><creatorcontrib>Hotta, Takamasa</creatorcontrib><creatorcontrib>Hamai, Kosuke</creatorcontrib><creatorcontrib>Furuya, Naoki</creatorcontrib><creatorcontrib>Yokoyama, Toshihide</creatorcontrib><creatorcontrib>Saito, Ryota</creatorcontrib><creatorcontrib>Nakamura, Atsushi</creatorcontrib><creatorcontrib>Masuda, Takeshi</creatorcontrib><creatorcontrib>Hamaguchi, Megumi</creatorcontrib><creatorcontrib>Kuyama, Shoichi</creatorcontrib><creatorcontrib>Honda, Ryoichi</creatorcontrib><creatorcontrib>Senoo, Tadashi</creatorcontrib><creatorcontrib>Nakanishi, Masamoto</creatorcontrib><creatorcontrib>Yamasaki, Masahiro</creatorcontrib><creatorcontrib>Ishikawa, Nobuhisa</creatorcontrib><creatorcontrib>Fujitaka, Kazunori</creatorcontrib><creatorcontrib>Kubota, Tetsuya</creatorcontrib><creatorcontrib>Kobayashi, Kunihiko</creatorcontrib><creatorcontrib>Isobe, Takeshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of hematology and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsubata, Yukari</au><au>Hotta, Takamasa</au><au>Hamai, Kosuke</au><au>Furuya, Naoki</au><au>Yokoyama, Toshihide</au><au>Saito, Ryota</au><au>Nakamura, Atsushi</au><au>Masuda, Takeshi</au><au>Hamaguchi, Megumi</au><au>Kuyama, Shoichi</au><au>Honda, Ryoichi</au><au>Senoo, Tadashi</au><au>Nakanishi, Masamoto</au><au>Yamasaki, Masahiro</au><au>Ishikawa, Nobuhisa</au><au>Fujitaka, Kazunori</au><au>Kubota, Tetsuya</au><au>Kobayashi, Kunihiko</au><au>Isobe, Takeshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study</atitle><jtitle>Journal of hematology and oncology</jtitle><addtitle>J Hematol Oncol</addtitle><date>2022-04-04</date><risdate>2022</risdate><volume>15</volume><issue>1</issue><spage>40</spage><epage>40</epage><pages>40-40</pages><artnum>40</artnum><issn>1756-8722</issn><eissn>1756-8722</eissn><abstract>Management of cancer-associated venous thromboembolism (VTE) is essential in treatment selection and cancer prognosis. However, to date, there is no method to assess the risk of VTE specifically associated with advanced lung cancer. Our aim was to create a new risk assessment scoring system that can predict the concomitant or incidence of VTE in advanced lung cancer. We used the dataset of 1008 patients with lung cancer in the Rising-VTE/NEJ037 study, of which 100 (9.9%) developed VTE. The items extracted in the multivariate analysis included female sex, adenocarcinoma, performance status, N factor, lymphocyte count, platelet count, prothrombin fragment 1 + 2, and diastolic blood pressure. This model had a maximum score of 8 points, with ≥ 5 points indicating a high risk of VTE. This simple risk-assessment model for VTE complications with advanced lung cancer could help identify cases that required monitoring for VTE.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>35379309</pmid><doi>10.1186/s13045-022-01259-7</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1756-8722
ispartof Journal of hematology and oncology, 2022-04, Vol.15 (1), p.40-40, Article 40
issn 1756-8722
1756-8722
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_2fea11230a9f4a7eade6668f5a8337d5
source Open Access: PubMed Central; Publicly Available Content Database (Proquest) (PQ_SDU_P3)
subjects Adenocarcinoma
Asymptomatic
Blood pressure
Cancer
Cancer therapies
Care and treatment
Cell number
Chemotherapy
Deep vein thrombosis
Female
Health aspects
Humans
Letter to the Editor
Lung cancer
Lung Neoplasms - complications
Lymphocytes
Multivariate analysis
Oncology, Experimental
Patients
Prognosis
Prospective Studies
Prothrombin
Prothrombin fragment 1 + 2
Pulmonary thromboembolism
Risk Assessment
Risk Factors
Risk-assessment model
Thrombin
Thromboembolism
Thrombosis
Venous Thromboembolism - etiology
title A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A43%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20new%20risk-assessment%20tool%20for%20venous%20thromboembolism%20in%20advanced%20lung%20cancer:%20a%20prospective,%20observational%20study&rft.jtitle=Journal%20of%20hematology%20and%20oncology&rft.au=Tsubata,%20Yukari&rft.date=2022-04-04&rft.volume=15&rft.issue=1&rft.spage=40&rft.epage=40&rft.pages=40-40&rft.artnum=40&rft.issn=1756-8722&rft.eissn=1756-8722&rft_id=info:doi/10.1186/s13045-022-01259-7&rft_dat=%3Cgale_doaj_%3EA699416750%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c660t-292e7af0ccabbe1b52cb952ac92ce331412138046a6fb00713b9902f09d298ee3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2651999562&rft_id=info:pmid/35379309&rft_galeid=A699416750&rfr_iscdi=true